BioXcell功能性抗體系列推薦-InVivoMAb anti-human PD-1 (CD279)
產(chǎn)品信息：
|
- 純度： >95%
- 內(nèi)毒素：< 2EU/mg
- 貨號：BE0188
- Clone: J116
|
 |
應(yīng)用類型：
in vitro PD-1 neutralization
in vivo PD-1 blockade in humanized mice
參考文獻(xiàn)：
1、"Programmed death-1 controls T cell survival by regulating oxidative metabolism" J Immunol 194(12): 5789-5800
2、"The Tol2 transposon system mediates the genetic engineering of T-cells with CD19-specific chimeric antigen receptors for B-cell malignancies" Gene Ther 22(2): 209-215.
3、"Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells" J Clin Invest 123(4): 1677-1693.
4、Singh, A., et al. (2012). "Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-gamma producing T cells" PLoS One 7(9): e44728.
5、"Programmed death (PD)-1 molecule and its ligand PD-L1 distribution among memory CD4 and CD8 T cell subsets in human immunodeficiency virus-1-infected individuals" Clin Exp Immunol 157(1): 90-97.
6、"Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis" J Immunol 181(1): 116-125.
BioXcell功能性抗體（清除、阻斷、中和）現(xiàn)貨團購中，>50mg大包裝爆款現(xiàn)貨！歡迎選購：https://www.univ-bio.com/sales-once-detail.html?id=1056
- CD8+T細(xì)胞在抗腫瘤免疫中的作用及CD8抗體的應(yīng)用
- 抗體助力葉酸靶向納米乳劑PFD@ZD-FA減輕TACE術(shù)后肝纖維化的研究
- CTLA-4抗體在細(xì)胞免疫調(diào)控和腫瘤免疫治療中的作用機制及應(yīng)用
- ATF3抗體助力揭示DRD1-ATF3/CHOP軸在GC-ONFH中的保護機制
- PD-L1抗體與PD-1抗體在作用機制、安全性、臨床應(yīng)用上的差異
- 重組單克隆抗體的技術(shù)優(yōu)勢與科研應(yīng)用指南
- APC共軛抗體在多色流式、免疫熒光等實驗中的應(yīng)用優(yōu)勢
- GR-1抗體在免疫調(diào)控中的作用及治療潛力
Copyright(C) 1998-2026 生物器材網(wǎng) 電話：021-64166852;13621656896 E-mail：info@bio-equip.com